surmount-1 tirzepatide trial weight loss non-diabetic

surmount-1 tirzepatide trial weight loss non-diabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled surmount-1 trial tirzepatide obesity without

Name: surmount-1 tirzepatide trial weight loss non-diabetic for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled surmount-1 trial tirzepatide obesity without
Brand: studiesandawardsltd.com
SKU: 80181922575
Price: 25.05 USD
Availability: InStock
Rating: 4.4383 (21 reviews)

SKU: 80181922575

4.4

USD25.05 USD56.05

Pay in 4 interest-free payments of $6.26 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 9 - Aug 14

Description

Starting Dose and Titration Schedule Retatrutide phase 2 used a structured titration: Weeks 1 to 4: 2 mg subcutaneous once weekly Weeks 5 to 8: 4 mg once weekly Weeks 9 to 12: 8 mg once weekly Week 13 onward: 12 mg once weekly (maximum dose) Gastrointestinal adverse events drove dose reductions in 15.7% of participants receiving 12 mg in the phase 2 trial